Optical Coherence Tomography Patents

Optical coherence tomography (OCT) patents cover OCT-technology (domain/source) innovations; OCT-angiography innovations; probe and application innovations; and image-processing, AI, and functional-OCT innovations — with IP held by ophthalmic-imaging companies, cardiovascular-imaging firms, and optics makers (in a field producing micron-resolution cross-sectional images of tissue using low-coherence light interferometry). WHY OCT: OCT is like an 'optical ultrasound' — it uses low-coherence near-infrared light interferometry to image tissue microstructure at micron-scale resolution, non-invasively and in real time; it has transformed OPHTHALMOLOGY (imaging retinal layers is now standard of care), and is important in CARDIOLOGY (intravascular imaging of coronary arteries), dermatology, and dentistry. MAJOR OCT PATENT HOLDERS: CARL ZEISS MEDITEC: the leading ophthalmic OCT (Cirrus), with a deep portfolio. HEIDELBERG ENGINEERING (Spectralis), TOPCON, OPTOVUE/VISIONIX, NIDEK (ophthalmic OCT). ABBOTT (acquired St. Jude/LightLab): intravascular/coronary OCT (OptisOCT). THORLABS (research OCT), and MIT/Fujimoto (foundational OCT — largely EXPIRED, an FTO opportunity). OCT technology/source, OCT angiography, probes/applications, and image-processing/AI/functional OCT are the core OCT patent domains — and swept-source OCT, OCTA, AI analysis, miniaturized probes, and new applications are the open whitespace.

OCT-domain (time/spectral/swept-source) innovations; light-source and interferometer innovations; OCT-angiography (OCTA) innovations; and resolution, speed, and depth innovations represent core OCT patent domains — and faster, deeper, higher-resolution imaging and dye-free angiography are the central technical advances. OCT-DOMAIN PATENTS: the core detection scheme and its evolution — TIME-DOMAIN OCT (early, slow), SPECTRAL-DOMAIN OCT (SD-OCT, uses a spectrometer — much faster, sensitive), and SWEPT-SOURCE OCT (SS-OCT, uses a rapidly tunable laser — even faster, deeper penetration, longer wavelength); the domain/architecture and improvements are foundational IP (much early-OCT IP is now expired). LIGHT-SOURCE / INTERFEROMETER PATENTS: the engine of OCT — broadband/superluminescent sources, rapidly SWEPT/tunable lasers (key for SS-OCT, e.g., VCSEL/akinetic swept sources), interferometer design, and detection/balanced detection; the swept-laser source is a high-value, differentiating component. OCT-ANGIOGRAPHY (OCTA) PATENTS: visualizing BLOOD FLOW/vasculature WITHOUT injected dye by detecting motion contrast between repeated OCT scans — OCTA algorithms (decorrelation/variance methods), motion correction, and depth-resolved vascular mapping; OCTA was a major advance and is a rich, valuable IP area. RESOLUTION / SPEED / DEPTH PATENTS: higher axial/lateral resolution, faster A-scan rates (megahertz OCT), wider field, and deeper imaging. Swept-source OCT, swept-laser sources, and OCT angiography (dye-free) are the highest-value technology IP because imaging speed/depth and OCTA define modern OCT performance and clinical value.

Probe and catheter innovations; image-processing and segmentation innovations; AI and disease-detection innovations; and functional-OCT, miniaturization, and application innovations represent additional OCT patent domains — and getting OCT into the body, analyzing the images, and extending its capabilities/applications are where much modern value sits. PROBE / CATHETER PATENTS: delivering OCT to tissues beyond the eye — INTRAVASCULAR OCT catheters (imaging coronary artery walls/stents, Abbott), endoscopic OCT probes, scanning optics, and miniaturized fiber-optic probes; the imaging probe/catheter is key for cardiology/GI applications. IMAGE-PROCESSING / SEGMENTATION PATENTS: turning raw scans into clinical information — retinal-layer SEGMENTATION, boundary detection, registration/motion correction, artifact removal, and quantitative metrics (e.g., retinal thickness maps); segmentation is core to ophthalmic OCT. AI / DISEASE-DETECTION PATENTS: machine-learning analysis of OCT — automated detection/grading of disease (diabetic retinopathy, AMD, glaucoma), AI segmentation, predictive analytics, and OCT/OCTA biomarkers; AI on OCT is a fast-growing, high-value IP area. FUNCTIONAL-OCT / MINIATURIZATION / APPLICATION PATENTS: functional extensions (Doppler OCT for flow, polarization-sensitive OCT for tissue properties, OCT elastography), miniaturized/handheld/HOME OCT (for monitoring), and new applications (dermatology, dentistry, intraoperative OCT). AI-based OCT analysis/disease detection, intravascular/endoscopic probes, and functional/miniaturized OCT are the highest-value application IP because automated analysis, in-body imaging, and new form factors/applications drive OCT's expanding clinical utility.

OCT startup IP strategy must navigate Zeiss/Heidelberg/Topcon/Abbott portfolios, extensive OCT prior art (OCT has been developed since the early 1990s — foundational MIT/Fujimoto patents have largely EXPIRED, an FTO opportunity, while incumbents hold dense modern portfolios), the technology (swept-source/OCTA) and probe challenges, the AI-analysis and regulatory (medical-device/SaMD) realities, the crowded ophthalmic market vs newer applications, and a landscape where OCT technology, OCTA, probes, AI, and functional OCT are the durable assets; understand that foundational OCT and basic SD-OCT are well-trodden/partly expired, so the durable IP is in swept-source advances, OCTA, AI analysis, miniaturized probes, functional OCT, and new applications, and that performance, AI/clinical validation, form factor, and FTO matter as much as patents; identify whitespace in AI, OCTA, miniaturization, and new applications. OCT STARTUP IP STRATEGY: FOUNDATIONAL OCT IS LARGELY EXPIRED — SWEPT-SOURCE, OCTA, AI, PROBES, AND NEW APPS ARE THE IP (AND AN FTO OPPORTUNITY): early OCT/SD-OCT patents have largely expired (use freely), so patent swept-source advances, OCTA, AI, miniaturized probes, and functional OCT — and exploit the expired-IP FTO opportunity (while respecting incumbents' modern portfolios); AI-BASED OCT ANALYSIS IS THE FASTEST-GROWING, HIGH-VALUE WHITESPACE: automated disease detection/segmentation/biomarkers on OCT/OCTA (with SaMD regulatory clearance) is the modern frontier — algorithm IP + validation data are the moat; OCT ANGIOGRAPHY (DYE-FREE) IS A RICH IP AREA: OCTA motion-contrast algorithms and vascular imaging are high-value and differentiating; SWEPT-SOURCE OCT AND SOURCES DIFFERENTIATE ON PERFORMANCE: faster/deeper SS-OCT and novel swept lasers (VCSEL/akinetic) are defensible technology IP; MINIATURIZED/HOME/HANDHELD OCT OPENS NEW MARKETS: portable and home-monitoring OCT (for chronic eye disease) is a growth whitespace; INTRAVASCULAR/ENDOSCOPIC PROBES EXTEND BEYOND THE EYE: catheter/probe IP enables cardiology/GI applications (Abbott's space) — high-value but capital-intensive; NEW APPLICATIONS ARE LESS CROWDED THAN OPHTHALMOLOGY: dermatology, dentistry, and intraoperative OCT offer whitespace vs the crowded retina market; REGULATORY/CLINICAL VALIDATION GATES MEDICAL OCT: device/SaMD clearance and clinical evidence matter as much as patents; WHEN TO PATENT: NOVEL TECHNOLOGY/ALGORITHM/PROBE WITH MEASURED PERFORMANCE: file once a method/device shows measured results (resolution + scan speed (A-scans/sec) + depth/penetration + OCTA quality + AI accuracy (sensitivity/specificity) + probe size/access + form factor) vs. SD-OCT/incumbent baselines — measured resolution/speed, OCTA/AI performance, and probe/form-factor are the critical OCT IP metrics; KEY FTO CHECKLIST: Zeiss Cirrus/Heidelberg Spectralis/Topcon ophthalmic OCT; Abbott intravascular OCT (Optis/LightLab); MIT/Fujimoto foundational OCT (largely EXPIRED — FTO opportunity); time/spectral-domain (SD-OCT)/swept-source (SS-OCT) domain; broadband/superluminescent source + swept/tunable laser (VCSEL/akinetic)/interferometer/balanced detection; OCT angiography OCTA decorrelation/motion-contrast algorithm; intravascular/endoscopic probe/catheter/scanning optics; retinal-layer segmentation/registration/quantitative maps; AI disease detection (DR/AMD/glaucoma)/biomarkers (SaMD); functional Doppler/polarization-sensitive/elastography OCT; miniaturized/handheld/home OCT; new applications dermatology/dentistry/intraoperative; OCT prior art + medical-device regulatory.